Market Cap 10.34B
Revenue (ttm) 0.00
Net Income (ttm) -380.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,883,209
Avg Vol 990,418
Day's Range N/A - N/A
Shares Out 79.70M
Stochastic %K 78%
Beta 0.84
Analysts Strong Sell
Price Target $150.83

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 53 83 09 63
Address:
7-11 Boulevard Haussmann, Paris, France
Jblack500
Jblack500 May. 29 at 5:40 PM
$ABVX @MaverikIT @No_Face_character @cynicaloptimist @IsabellaDC @BustaCapital @WAJeff vol above avg, channel move nice but also fairly irrelevant since all that matters is p3 data coming this q
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 29 at 5:25 PM
$SLS $ABBV - this Manipulated $9 stock / $1.7B MCAP equity - is a $90 Stock / $17B and Climbing the Instant Gps Phase 3 Results are Announced - they are Coming - Will Be ANY DAY NOW - They Are Inevitable. - Be HoDLING - when we get the PR Phase 3 Results are worth every nickel of $40B to BP Short Market Manipulation offering the Investment Opportunity of a Lifetime. $ABVX was a $5 Stock - Bumping around $5 - $8 and then had Risen to $10 in the days Right before Its P3 was Announced. T1 TRADING HALT +600% GAP UP to $60 and it Kept Climbing to a high of $148 as the market digested BO Value.
0 · Reply
dutchiestocks
dutchiestocks May. 29 at 3:55 PM
$ABVX 👀wow big buys! 💪🏻
0 · Reply
Elades
Elades May. 29 at 10:27 AM
$ABVX 🚀 all the way to 200$
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 29 at 12:38 AM
$SLS $ABVX $5 to $148 Based on P3 Data Something Very Similar is about to Happen Here --- Be HOLDING. Could See the 80th Event PR any day now.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 28 at 6:09 PM
$SLS $ABBV review the historical pricing, $ABVX was scraping around $5 and change in the days ahead of releasing its Phase 3 Trial Results, the Share price had risen to $10 Per Share - the Day the PR HIT. - INSTANT T1 TRADING HALT and a GAP UP +600% - Share Price OPENED at $60 --- from $10 to $60 +600% in an Instant and the Share Price continued to Climb to a HIGH of $148 per share From $5 and Change to $148 - a Market Cap of $12.9B ... BILLY all Based on the Value of a P3 Trial Result. SOMETHING VERY SIMILAR BUT BIGGER IS ABOUT TO HAPPEN HERE. This is why we are now seeing the fud.
1 · Reply
dutchiestocks
dutchiestocks May. 28 at 5:55 PM
$ABVX great seeing big orders rolling through at the lowest price they can buy them due to market makers tapering price for them by some low volume sells. That can only last so long since there shares to sell are depleting and the real market low supply takes over. I am feeling more comfortable by the hour 🤗
0 · Reply
StockJock73
StockJock73 May. 28 at 5:44 PM
$ABVX $SLS a little louder for a AHOLE shorty bears in the back !!!
0 · Reply
bikechain
bikechain May. 28 at 5:41 PM
$SLS What those SA hacks don’t want newbies to know is: —The FDA approved the trial design to begin with. (This was the time to say the n factor was too small.) —At the #60 IA unblinding the FDA complemented the SLS team for a WELL DESIGNED trial, and there was no need to change anything. Just carry on to #80. —It was the FDA who agreed to moving the dosing from 1 year to 2 years, 2 years to 3 years, and 3 years to “UNLIMITED years” In the end it’s the FDA who has the final say. But these “clowns” want newbies to think it’s this very same supportive FDA who is going to pronounce “failure”. It’s beyond laughable. We know these guys are paid hacks, paid to distort the obvious. NOTE: How many paid hacks tried to distort ABVX and others on the cusp of success? Maybe some of you know (I wasn’t there, but I’m sure there were). $ABVX
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 28 at 4:08 PM
$SLS $SLS You can review the historical pricing, $ABVX was scraping around $5 and change in the days ahead of releasing its Phase 3 Trial Results, the Share price had risen to $10 Per Share - the Day the PR HIT. - INSTANT T1 TRADING HALT and a GAP UP +600% - Share Price OPENED at $60 --- from $10 to $60 +600% in an Instant and the Share Price continued to Climb to a HIGH of $148 per share From $5 and Change to $148 - a Market Cap of $12.9B ... BILLY all Based on the Value of a P3 Trial Result. SOMETHING VERY SIMILAR BUT BIGGER IS ABOUT TO HAPPEN HERE.
1 · Reply
Latest News on ABVX
ABIVAX Société Anonyme Earnings release: Q1 2026

May 22, 2026, 11:40 AM EDT - 7 days ago

ABIVAX Société Anonyme Earnings release: Q1 2026


ABIVAX Société Anonyme Earnings release: Q1 2026

May 22, 2026, 11:40 AM EDT - 7 days ago

ABIVAX Société Anonyme Earnings release: Q1 2026


Abivax put volume heavy and directionally bearish

2026-05-12T18:20:45.000Z - 17 days ago

Abivax put volume heavy and directionally bearish


Abivax call volume above normal and directionally bullish

2026-04-28T14:50:09.000Z - 4 weeks ago

Abivax call volume above normal and directionally bullish


Abivax price target raised to EUR 120 from EUR 88 at Oddo BHF

2026-04-09T09:15:22.000Z - 7 weeks ago

Abivax price target raised to EUR 120 from EUR 88 at Oddo BHF


This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

Tue, 07 Apr 2026 15:00:00 -0400 - 7 weeks ago

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?


Abivax appoints Michael Nesrallah as chief commercial officer

2026-04-01T20:21:24.000Z - 2 months ago

Abivax appoints Michael Nesrallah as chief commercial officer

TAK


2 Healthcare Stocks That Could Soar Over the Next 5 Years

Thu, 26 Mar 2026 17:30:00 -0400 - 2 months ago

2 Healthcare Stocks That Could Soar Over the Next 5 Years


Abivax price target raised to $148 from $142 at Barclays

2026-03-24T09:30:12.000Z - 2 months ago

Abivax price target raised to $148 from $142 at Barclays


ABIVAX Société Anonyme Annual report: Q4 2025

Mar 23, 2026, 12:45 PM EDT - 2 months ago

ABIVAX Société Anonyme Annual report: Q4 2025


ABIVAX Société Anonyme Earnings release: Q4 2025

Mar 23, 2026, 12:45 PM EDT - 2 months ago

ABIVAX Société Anonyme Earnings release: Q4 2025


2 Healthcare Stocks to Buy Before They Get Bought Out

Fri, 20 Mar 2026 05:34:00 -0400 - 2 months ago

2 Healthcare Stocks to Buy Before They Get Bought Out


Abivax initiated with a Buy at Jefferies

2026-03-16T00:15:14.000Z - 2 months ago

Abivax initiated with a Buy at Jefferies


2 Reasons Abivax Stock Could 10X by 2036

Fri, 27 Feb 2026 14:45:00 -0500 - 3 months ago

2 Reasons Abivax Stock Could 10X by 2036


Abivax initiated with an Underperform at Wedbush

2026-02-24T11:52:54.000Z - 3 months ago

Abivax initiated with an Underperform at Wedbush


Wedbush initiates Abivax with an Underperform, urges caution

2026-02-24T11:51:55.000Z - 3 months ago

Wedbush initiates Abivax with an Underperform, urges caution


Abivax initiated with a Neutral at Wedbush

2026-02-24T11:45:15.000Z - 3 months ago

Abivax initiated with a Neutral at Wedbush


Abivax presents preclinical data for obefazimod

2026-02-22T18:55:09.000Z - 3 months ago

Abivax presents preclinical data for obefazimod

ABVX


Better Long-Term Buy: This Emerging Player or the Industry Leader?

Fri, 30 Jan 2026 15:30:00 -0500 - 4 months ago

Better Long-Term Buy: This Emerging Player or the Industry Leader?


Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

Jan 20, 2026, 6:01 AM EST - 4 months ago

Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

ABVX LLY


Prediction: This Healthcare Stock Could Soar by 72% in 2026

Mon, 19 Jan 2026 15:45:00 -0500 - 4 months ago

Prediction: This Healthcare Stock Could Soar by 72% in 2026


Abivax stock rockets 30% on Eli Lilly takeover speculation

Jan 12, 2026, 9:32 AM EST - 4 months ago

Abivax stock rockets 30% on Eli Lilly takeover speculation

LLY


Abivax shares soar 23% as media report reignites M&A chatter

Jan 12, 2026, 4:38 AM EST - 4 months ago

Abivax shares soar 23% as media report reignites M&A chatter

LLY


Abivax Provides 2026 Corporate Outlook

Jan 7, 2026, 4:05 PM EST - 5 months ago

Abivax Provides 2026 Corporate Outlook


Why Abivax Stock Was on Fire Today

Mon, 22 Dec 2025 19:09:18 -0500 - 5 months ago

Why Abivax Stock Was on Fire Today


Abivax to be Added to Nasdaq Biotechnology Index

Dec 18, 2025, 4:05 PM EST - 5 months ago

Abivax to be Added to Nasdaq Biotechnology Index


ABIVAX Société Anonyme Earnings release: Q3 2025

Dec 15, 2025, 11:45 AM EST - 5 months ago

ABIVAX Société Anonyme Earnings release: Q3 2025


French biotech Abivax's shares climb on Eli Lilly bid rumors

Dec 10, 2025, 5:52 AM EST - 6 months ago

French biotech Abivax's shares climb on Eli Lilly bid rumors

LLY


2 Under-the-Radar Stocks That Have Soared This Year

Tue, 09 Dec 2025 16:45:00 -0500 - 6 months ago

2 Under-the-Radar Stocks That Have Soared This Year


ABIVAX Société Anonyme Press release: FY 2025

Oct 6, 2025, 9:00 AM EDT - 8 months ago

ABIVAX Société Anonyme Press release: FY 2025


ABIVAX Société Anonyme Slides: FY 2025

Oct 6, 2025, 9:00 AM EDT - 8 months ago

ABIVAX Société Anonyme Slides: FY 2025


Abivax Presents First Half 2025 Financial Results

Sep 8, 2025, 4:00 PM EDT - 9 months ago

Abivax Presents First Half 2025 Financial Results


ABIVAX Société Anonyme Quarterly report: Q2 2025

Sep 8, 2025, 11:45 AM EDT - 9 months ago

ABIVAX Société Anonyme Quarterly report: Q2 2025


ABIVAX Société Anonyme Earnings release: Q2 2025

Sep 8, 2025, 11:45 AM EDT - 9 months ago

ABIVAX Société Anonyme Earnings release: Q2 2025


How Hedge Funds Won Big on an Obscure Drugmaker

Aug 30, 2025, 5:30 AM EDT - 9 months ago

How Hedge Funds Won Big on an Obscure Drugmaker


Abivax Announces Closing of $747.5 Million Public Offering

Jul 28, 2025, 4:15 PM EDT - 10 months ago

Abivax Announces Closing of $747.5 Million Public Offering


Abivax Announces Launch of Public Offering

Jul 23, 2025, 4:15 PM EDT - 11 months ago

Abivax Announces Launch of Public Offering


ABIVAX Société Anonyme Transcript: Study Result

Jul 22, 2025, 4:30 PM EDT - 11 months ago

ABIVAX Société Anonyme Transcript: Study Result


ABIVAX Société Anonyme Press release: Study Result

Jul 22, 2025, 4:30 PM EDT - 11 months ago

ABIVAX Société Anonyme Press release: Study Result


ABIVAX Société Anonyme Slides: Study Result

Jul 22, 2025, 4:30 PM EDT - 11 months ago

ABIVAX Société Anonyme Slides: Study Result


ABIVAX Société Anonyme Transcript: AGM 2025

Jun 6, 2025, 4:00 AM EDT - 1 year ago

ABIVAX Société Anonyme Transcript: AGM 2025


ABIVAX Société Anonyme Slides: FY 2025

Jun 6, 2025, 4:00 AM EDT - 1 year ago

ABIVAX Société Anonyme Slides: FY 2025


Abivax Presents First Quarter 2025 Financial Results

Jun 2, 2025, 4:00 PM EDT - 1 year ago

Abivax Presents First Quarter 2025 Financial Results


ABIVAX Société Anonyme Quarterly report: Q1 2025

Jun 2, 2025, 11:40 AM EDT - 1 year ago

ABIVAX Société Anonyme Quarterly report: Q1 2025


ABIVAX Société Anonyme Earnings release: Q1 2025

Jun 2, 2025, 11:40 AM EDT - 1 year ago

ABIVAX Société Anonyme Earnings release: Q1 2025


ABIVAX Société Anonyme Slides: Corporate Presentation

Jun 2, 2025, 7:00 AM EDT - 1 year ago

ABIVAX Société Anonyme Slides: Corporate Presentation


ABIVAX Société Anonyme Slides: Corporate Presentation

Mar 24, 2025, 3:00 PM EDT - 1 year ago

ABIVAX Société Anonyme Slides: Corporate Presentation


ABIVAX Société Anonyme Annual report: H2 2024

Mar 24, 2025, 12:40 PM EDT - 1 year ago

ABIVAX Société Anonyme Annual report: H2 2024


ABIVAX Société Anonyme Earnings release: H2 2024

Mar 24, 2025, 12:40 PM EDT - 1 year ago

ABIVAX Société Anonyme Earnings release: H2 2024


Abivax Announces Full Year 2024 Financial Results

Mar 24, 2025, 3:30 AM EDT - 1 year ago

Abivax Announces Full Year 2024 Financial Results


Abivax Publishes 2025 Financial Calendar

Jan 28, 2025, 2:30 AM EST - 1 year ago

Abivax Publishes 2025 Financial Calendar


Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Nov 19, 2024, 4:30 PM EST - 1 year ago

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq


Abivax presents third quarter 2024 key financial information

Nov 14, 2024, 4:01 PM EST - 1 year ago

Abivax presents third quarter 2024 key financial information


Jblack500
Jblack500 May. 29 at 5:40 PM
$ABVX @MaverikIT @No_Face_character @cynicaloptimist @IsabellaDC @BustaCapital @WAJeff vol above avg, channel move nice but also fairly irrelevant since all that matters is p3 data coming this q
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 29 at 5:25 PM
$SLS $ABBV - this Manipulated $9 stock / $1.7B MCAP equity - is a $90 Stock / $17B and Climbing the Instant Gps Phase 3 Results are Announced - they are Coming - Will Be ANY DAY NOW - They Are Inevitable. - Be HoDLING - when we get the PR Phase 3 Results are worth every nickel of $40B to BP Short Market Manipulation offering the Investment Opportunity of a Lifetime. $ABVX was a $5 Stock - Bumping around $5 - $8 and then had Risen to $10 in the days Right before Its P3 was Announced. T1 TRADING HALT +600% GAP UP to $60 and it Kept Climbing to a high of $148 as the market digested BO Value.
0 · Reply
dutchiestocks
dutchiestocks May. 29 at 3:55 PM
$ABVX 👀wow big buys! 💪🏻
0 · Reply
Elades
Elades May. 29 at 10:27 AM
$ABVX 🚀 all the way to 200$
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 29 at 12:38 AM
$SLS $ABVX $5 to $148 Based on P3 Data Something Very Similar is about to Happen Here --- Be HOLDING. Could See the 80th Event PR any day now.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 28 at 6:09 PM
$SLS $ABBV review the historical pricing, $ABVX was scraping around $5 and change in the days ahead of releasing its Phase 3 Trial Results, the Share price had risen to $10 Per Share - the Day the PR HIT. - INSTANT T1 TRADING HALT and a GAP UP +600% - Share Price OPENED at $60 --- from $10 to $60 +600% in an Instant and the Share Price continued to Climb to a HIGH of $148 per share From $5 and Change to $148 - a Market Cap of $12.9B ... BILLY all Based on the Value of a P3 Trial Result. SOMETHING VERY SIMILAR BUT BIGGER IS ABOUT TO HAPPEN HERE. This is why we are now seeing the fud.
1 · Reply
dutchiestocks
dutchiestocks May. 28 at 5:55 PM
$ABVX great seeing big orders rolling through at the lowest price they can buy them due to market makers tapering price for them by some low volume sells. That can only last so long since there shares to sell are depleting and the real market low supply takes over. I am feeling more comfortable by the hour 🤗
0 · Reply
StockJock73
StockJock73 May. 28 at 5:44 PM
$ABVX $SLS a little louder for a AHOLE shorty bears in the back !!!
0 · Reply
bikechain
bikechain May. 28 at 5:41 PM
$SLS What those SA hacks don’t want newbies to know is: —The FDA approved the trial design to begin with. (This was the time to say the n factor was too small.) —At the #60 IA unblinding the FDA complemented the SLS team for a WELL DESIGNED trial, and there was no need to change anything. Just carry on to #80. —It was the FDA who agreed to moving the dosing from 1 year to 2 years, 2 years to 3 years, and 3 years to “UNLIMITED years” In the end it’s the FDA who has the final say. But these “clowns” want newbies to think it’s this very same supportive FDA who is going to pronounce “failure”. It’s beyond laughable. We know these guys are paid hacks, paid to distort the obvious. NOTE: How many paid hacks tried to distort ABVX and others on the cusp of success? Maybe some of you know (I wasn’t there, but I’m sure there were). $ABVX
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 28 at 4:08 PM
$SLS $SLS You can review the historical pricing, $ABVX was scraping around $5 and change in the days ahead of releasing its Phase 3 Trial Results, the Share price had risen to $10 Per Share - the Day the PR HIT. - INSTANT T1 TRADING HALT and a GAP UP +600% - Share Price OPENED at $60 --- from $10 to $60 +600% in an Instant and the Share Price continued to Climb to a HIGH of $148 per share From $5 and Change to $148 - a Market Cap of $12.9B ... BILLY all Based on the Value of a P3 Trial Result. SOMETHING VERY SIMILAR BUT BIGGER IS ABOUT TO HAPPEN HERE.
1 · Reply
jm0olah
jm0olah May. 28 at 3:51 PM
$ABVX halted?
0 · Reply
bluenormas
bluenormas May. 28 at 12:22 PM
0 · Reply
BrianRix
BrianRix May. 28 at 8:55 AM
$ABVX nice... 140s incoming
0 · Reply
Stonkhausen
Stonkhausen May. 27 at 11:06 PM
$ABVX so quiet in here, I like it 🤫
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 5:28 PM
$SLS Calling it now. $100 Per Share in the days After the Phase 3 Results are announced. - We can deduce from Known Facts, GPS Phase 3 Patient MOS > 30.5 months / BAT for Control - Aza+VEN Failed 3 Large Trials - Ceo on record, along with 3 Physicians Treating actual Patients, MOS for BAT is Dismal ~ 8 months ~ 11 months INCLUDING Transplant. -- Gps is getting the FDA Green light to treat 100,000 AML Patients Currently in Remission. $28B Total Addressable Market - right out of the Gate. The SLS Run will Make the $ABVX run from $5 to $148 look Anemic.
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 5:10 AM
$SLS $ABBV $ABVX When the 80th EVENT is Announced, this is some of the Revenue Institutional Investors and Big Pharma is Looking at.
0 · Reply
dutchiestocks
dutchiestocks May. 26 at 7:17 PM
$ABVX eu volume today was 2,5x average... The two days before were 1,5x and 1,25x average. Volume preceeds price and for sure something is cooking. Data is stellar already, just need a little more confirmation with the maintenance data published. I am curious to find out which BP hooked them and will real them in on that day.
1 · Reply
DonCorleone77
DonCorleone77 May. 26 at 7:00 PM
$ABVX Attached is a Truist analyst note regarding ABVX issued today.
0 · Reply
Jblack500
Jblack500 May. 26 at 4:31 PM
$HALO $ABVX $GILD $MRK $ARWR ELAN ANIP. halo back to 80. Abvx outstanding data release and key p3 coming. Gild knocking on 50 day...volume and inflow will pickup when it climbs back over. Chart looking good.
0 · Reply
BanditQ
BanditQ May. 26 at 4:19 PM
$ABVX that fkn 3 month chart 🤣
0 · Reply
Trainguy1
Trainguy1 May. 26 at 1:09 PM
$ABVX The catalyst we are currently waiting for is topline 44-week maintenance results from the Phase 3 ABTECT clinical trial in moderate-to-severely active ulcerative colitis. The readout will probably occur at the end of June 2026. If the results are good, ABVX will develop and submit a New Drug Application (NDA) to the FDA and a Marketing Authorization Application (MAA) to the EMA. In the meantime, the corporate update linked below came out last week. It’s a good read. https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports
1 · Reply
crymoreplz
crymoreplz May. 26 at 8:46 AM
$ABVX this biztch ass always bo bo bo but no bo for almost a year.
0 · Reply